Importantly, the modest improvements that we observed in risk reclassification with NT-proBNP concentration assessment applied similarly across the absolute risk thresholds used in different clinical guidelines.1, 2, 3, 4 In particular, NT-proBNP concentration assessment improved the specificity of risk prediction by appropriately downclassifying the clinical risk category of many individuals who did not go on to develop cardiovascular disease outcomes. The gene discussed is NPPB; the disease is cardiovascular disorder.